Notably, a SEZ6-targeted antibody–drug conjugate demonstrated clinical efficacy in a phase I trial for patients with advanced SCLC and NENs (NCT05599984; ref. 36) as did an SSTR2-targeting radiopharmaceutical in a phase Ib trial for GEP-NENs (NCT05477576; ref. 37). This evidence concerns the gene SSTR2 and small cell lung carcinoma.